New European patent approval for Episurf Medical

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Surgical Kit for Repair of Articular Surfaces in the Talocrural Joint Including Surgical Saw Guide, covers Episurf Medical’s ankle implant Episealer® Talus and related surgical tools including a novel osteotomy guide for surgical access to the difficult to reach talar bone.

"Episurf’s implant technology has been adapted to the ankle joint through the development of Episealer® Talus. This is the first European patent with a focus on the Episealer® Talus technology. The patent comes at a suitable timepoint, as the Episealer® Talus is currently undergoing the CE mark review process”, comments Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 24 July 2019.